Protein Predicts Sickle-Cell Danger
Posted on: Tuesday, 3 January 2006, 03:02 CST
By Harder, Ben
PROGNOSTIC BIOMARKERS
A biological marker of heart trouble can be used to identify sickle-cell anemia patients who are at greatest risk of developing a serious complication.
Pulmonary hypertension-high blood pressure of the arteries in the lungs-puts stress on the heart and is a major cause of disability and death among sickle-cell patients. Doctors can diagnose pulmonary hypertension using an echocardiogram, but they have difficulty predicting which patients will develop it.
To try a different approach, Roberto Machado of the National Heart, Lung, and Blood Institute in Bethesda, Md., and his colleagues tested blood samples from 275 volunteers for B-type natriuretic peptide (BNP). In patients with other disorders, the heart is known to overproduce that protein when it has difficulty pumping.
In sickle-cell patients with pulmonary hypertension, the average BNP concentration was 206 picograms per milliliter (pg/ml). By contrast, average BNP was just 29 pg/ml in healthy volunteers and 46 pg/ml in sickle-cell patients who hadn't developed the blood- pressure disorder, Machado's team found.
To test BNP's value as a prognostic tool, Machado's team then measured the protein in blood samples taken in 1996 from 121 other sickle-cell patients. The researchers found that patients who had at least 160 pg/ml BNP in 1996 were three times as likely to have died by 2005 as patients with lower BNP levels were. -B.H.
Copyright Science Service, Incorporated Dec 24-Dec 31, 2005
Source: Science News
Related Articles
- Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease
- NIH Halts Trial Of Viagra As Sickle Cell Treatment
- Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
- DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
- Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
- Anthera Receives IND Approval From FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
- Sickle Cell Blood Test Developed
- New Studies in Patients With Sickle Cell Disease Who Develop Pulmonary Hypertension-Recruiting Now for Clinical Trials
- Blood Test Detects Sickle Cell Disease Prognosis
- New Predictor of Deadly Complication Identified in Sickle Cell Patients
 |
 |
User Comments (0)
RSS Feeds